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Targeting the actin cytoskeleton: selective antitumor
action via trapping PKCe
F Foerster1, S Braig1, C Moser1, R Kubisch1, J Busse2, E Wagner2, E Schmoeckel3, D Mayr3, S Schmitt4, S Huettel3, H Zischka4,
R Mueller5 and AM Vollmar*,1
Targeting the actin cytoskeleton (CSK) of cancer cells offers a valuable strategy in cancer therapy. There are a number of natural
compounds that interfere with the actin CSK, but the mode of their cytotoxic action and, moreover, their tumor-specific
mechanisms are quite elusive. We used the myxobacterial compound Chondramide as a tool to first elucidate the mechanisms of
cytotoxicity of actin targeting in breast cancer cells (MCF7, MDA-MB-231). Chondramide inhibits cellular actin filament dynamics
shown by a fluorescence-based analysis (fluorescence recovery after photobleaching (FRAP)) and leads to apoptosis
characterized by phosphatidylserine exposure, release of cytochrome C from mitochondria and finally activation of caspases.
Chondramide enhances the occurrence of mitochondrial permeability transition (MPT) by affecting known MPT modulators:
Hexokinase II bound to the voltage-dependent anion channel (VDAC) translocated from the outer mitochondrial membrane to the
cytosol and the proapoptotic protein Bad were recruited to the mitochondria. Importantly, protein kinase C-e (PKCe),
a prosurvival kinase possessing an actin-binding site and known to regulate the hexokinase/VDAC interaction as well as Bad
phosphorylation was identified as the link between actin CSK and apoptosis induction. PKCe, which was found overexpressed in
breast cancer cells, accumulated in actin bundles induced by Chondramide and lost its activity. Our second goal was to
characterize the potential tumor-specific action of actin-binding agents. As the nontumor breast epithelial cell line MCF-10A in
fact shows resistance to Chondramide-induced apoptosis and notably express low level of PKCe, we suggest that trapping PKCe
via Chondramide-induced actin hyperpolymerization displays tumor cell specificity. Our work provides a link between targeting
the ubiquitously occurring actin CSK and selective inhibition of pro-tumorigenic PKCe, thus setting the stage for actin-stabilizing
agents as innovative cancer drugs. This is moreover supported by the in vivo efficacy of Chondramide triggered by abrogation of
PKCe signaling shown in a xenograft breast cancer model.
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The actin cytoskeleton (CSK) plays a crucial role in
intracellular transport processes, migration of cells and
cytokinesis. These processes require a highly dynamic
behavior of the actin CSK that involves polymerization and
depolymerization of actin filaments. Monomeric actin (G-
actin) polymerizes in a head-to-tail manner to form helical
actin filaments (F-actin) and the equilibrium between G-actin
and F-actin is tightly regulated by so-called actin-binding
proteins.1 Besides being pivotal for cell motility and division,
there is some evidence that actin CSK is also involved in cell
death induction, but the underlying mechanisms and signaling
molecules are not identified in detail.1
One interesting candidate linking the actin CSK and cell
death is protein kinase C-e (PKCe), a serine–threonine kinase
of the PKC family2 known to contain an actin-binding site.3
PKCe is distributed in several tissues like heart and brain,4,5
and it is also overexpressed in a broad range of tumor
malignancies like breast, stomach and gliomas.6–8 Because
of its distinct functions in proliferation and prosurvival
signaling processes, PKCe is an established oncoprotein
and a promising target for anticancer therapy.9,10 In this
context, PKCe affects targets that regulate cell survival such
as the transcription factors NF-kB and Stat3 or the Bcl-2
protein Bad (Bcl2-associated death promoter).9–12 Bad is a
proapoptotic BH3-only protein from the Bcl2-like gene family
that is inactive when phosphorylated (Ser112) by kinases
such as PKCe.13 Moreover, PKCe controls the linkage
between the glycolytic enzyme Hexokinase II (HkII) and the
voltage-dependent anion channel (VDAC) in mitochondria
that is thought to be specific for tumor cells.12,14 VDAC, a
channel located in the outer mitochondrial membrane facil-
itating the transport of small molecules, and hexokinase II,
phosphorylating glucose as a rate-limiting step in glycolysis,15
are both discussed for their roles in malignancy.15,16
Importantly, not only VDAC/HkII interaction but also Bad
contribute to the regulation of the mitochondrial permeability
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transition (MPT).14,17,18 This cell death eliciting process is
initiated by an increased permeability of the mitochondrial
inner membrane causing a depletion of the mitochondrial
membrane potential, a net water influx into the mitochondrial
matrix (‘swelling’) and finally the distension and rupture of the
outer membrane.19–23 The outer membrane damage leads to
the release of cytochrome C from the intermembrane space of
mitochondria into the cytosol, activation of the initiator
caspase 9 and finally to the induction of apoptosis.24 Although
several molecular aspects of the MPT are still under debate,
several modulators of this process are known, for example,
cyclosporin A as the ‘proto-type’ inhibitor of calcium-induced
MPT.25,26
Roy et al.17 showed that the dephosphorylated, active form
of Bad leads to MPT, and also that VDAC is thought to
participate in this process.16 HkII binding to VDAC, on the
other hand, stabilizes VDAC and prevents MPT and apopto-
sis.14 Thus, disrupting the VDAC/HkII complex as well as
activation of Bad could be attractive strategies to selectively
kill tumor cells via the MPT. In this work we aimed to
characterize and understand the molecular link between actin
CSK and induction of apoptotic processes. To this end we
hypothesized that PKCe possessing an actin-binding site
could be a signaling molecule bridging actin CSK and cell
death. We used Chondramide A (ChA), a myxobacterial
cyclodepsipeptide isolated from Chondromyces crocatus that
is27 known to induce polymerization of actin,27,28 as a
chemical tool to potentially affect PKCe-mediated cell death
induction. Chondramide has been shown to inhibit cancer cell
proliferation,28,29 but closer mechanistic insights are not
available.
In fact, our study shows that overpolymerization of actin
CSK via Chondramide leads to inhibition of a tumor-specific
PKCe signaling pathway, resulting in the induction of MPT and
apoptosis in vitro as well as in a xenograft breast cancer
mouse model in vivo. These data uncover the potential of
actin-binding drugs in cancer therapy.
Results
Chondramide inhibits actin dynamics and induces
apoptosis via the intrinsic pathway. The dynamics of
globular and filamentous actin equilibrium have been
analyzed using the fluorescence recovery after photo-
bleaching (FRAP) technique: a distinct region of MCF7
mammary cancer cells transfected with green fluorescent
protein (GFP)-tagged b-actin has been bleached by laser
(488 nm) and the actin filament dynamics were observed by
time lapse microscopy (Figure 1b). Untreated cells recover
from photobleaching within seconds seen by the rapid
disappearance of the bleached area (Figure 1b upper
panel, white arrows). In contrast, cells treated with
300 nM ChA (Figure 1a) for 30 min display a massive
reduction of the mobile, globular actin fraction (Figure 1b
lower panel, white arrows). Quantification of fluorescence
recovery confirms a distinct abrogation of actin filament
dynamics by ChA (Figure 1b, graph). Finally, ChA treat-
ment time dependently induces agglomeration of globular
actin that results in formation of actin lumps, as shown in
Figure 1c.
Besides affecting the actin CSK, ChA treatment (300 nM,
48 h) induces apoptosis in both MCF7 and MDA-MB-231
mammary cancer cells. Cell death was quantified using an
Annexin V/PI co-staining assay (Figure 2a). ChA treatment
(300 nM, 24 h) leads to a depletion of mitochondrial
membrane potential (DCm) analyzed by the use of the
mitochondrial selective dye JC-1 (Figure 2b). Fluorescence
profiles of both cell lines show a shift toward green
fluorescence of JC-1 (shift to the left) after ChA treatment,
indicating a decrease in mitochondrial membrane potential. In
line with disruption of mitochondrial membrane potential, ChA
treatment (300 nM) results in a release of cytochrome C from
the mitochondria in both cell lines. Figure 2c shows FACS
analysis of cytochrome C remaining in the mitochondria of
cells treated with ChA for 24 h compared with untreated cells.
Accordingly, downstream signaling of cytochrome C release,
namely activation of caspases, was evaluated. Western blot
analysis shows a decrease of pro-caspase 9 and the cleavage
of poly(ADP-ribose) polymerase (PARP), a well-known
substrate of effector caspases, in cells treated with 300 nM
ChA (24 h) (Figure 2d). In sum, Figure 2 demonstrates that
ChA induces cell death via the intrinsic apoptosis pathway.
Chondramide induces translocation of HkII from
mitochondria and dephosphorylation of Bad pointing
to a role of the MPT. As ChA depleted DCm and induced
mitochondrial cytochrome C release in mammary cancer
cells, both hallmarks of the MPT, we focused on major
players involved in this process. VDAC, which is localized at
the outer mitochondrial membrane, interacts with HkII,
thereby negatively modulating MPT and preventing apopto-
sis.15 We found that the binding of HkII and VDAC is
impaired by ChA (Figure 3a). HkII colocalizes with mitochon-
dria shown as a distinct dot-like pattern in control cells. In
contrast, cells treated with 300 nM ChA displayed a rather
diffuse localization of HkII, suggesting a disruption of the
mitochondrial VDAC/HkII interaction. Western blot experi-
ments support this notion as decreased protein levels of HkII
were found in the mitochondrial fraction of cells treated with
ChA (300 nM, 6 and 24 h) (Figure 3b).
Moreover, ChA affects a further regulator of the MPT, that
is, the Bcl-2 protein Bad.17 Protein level of Ser-112
phosphorylated, inactive Bad decreased dose dependently
after treatment of cells with ChA (100 and 300 nM, 6 h) with
constant total Bad protein levels (Figure 3c). Consequently, in
cells treated with ChA an intensified colocalization of Bad with
mitochondria was observed in comparison with untreated
cells (Figure 3d), supporting the idea that proapoptotic,
mitochondrial Bad is increased by chondramide because of
abrogation of the inactive, phosphorylated form of Bad.
Finally, the involvement of the MPT in ChA-induced cell
death was further supported by a set of experiments using
isolated mitochondria of untreated and ChA-treated MDA-MB-
231 cells. In mitochondria isolated from untreated and ChA-
treated cells, MPT could be induced by 400 mM Ca2þ (data
not shown). Importantly, cyclosporin A efficiently blocked the
Ca2þ -induced loss of DCm (Supplementary Figure 1A) and
confirms participation of the MPT in isolated mitochondria
from control cells (Supplementary Figure 1B). In contrast,
isolated mitochondria from ChA-treated cells only weakly
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responded toward the inhibitory action of cyclosporin A. A
progressing depletion of DCm coincided with an increasing
extent of mitochondria that have undergone swelling (i.e.,
MPT) (Supplementary Figure 1A and 1B).
Thus, by altering known modulators of the MPT, ChA leads
to a release of cytochrome C from mitochondria. The MPT-
blocking HkII/VDAC interaction is disrupted, Bad localizes
to mitochondria and cyclosporin A inhibition of the MPT is
Figure 1 Chondramide A (ChA) inhibits actin dynamics and leads to agglomeration of actin. (a) Molecular structure of ChA. (b) MCF7 cells were transfected with mGFP-
b-actin and treated with 300 nM ChA for 30 min. The mobile actin fraction was quantified by FRAP analysis. (Upper panel) White arrows indicate the photobleached area in
representative images (Ctrl, untreated cells; Ch300, cells treated with 300 nM ChA). (Lower panel) Values represent the % fluorescence recovery over time of mGFP-b-actin
after photobleach. (c) Time course of actin hyperpolymerization of MCF7 cells expressing mGFP-b-actin and treated with 300 nM ChA (Ch300) for 0.5, 6 and 24 h. Scale bar
indicates 10mm. Each experiment was independently performed three times
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Figure 2 Chondramide A (ChA) induces apoptosis in breast cancer cell lines via the intrinsic mitochondrial pathway. (a) MCF-7 as well as MDA-MB-231 cells were treated
with ChA (300 nM, 48 h) and analyzed for apoptotic cell death by staining with Annexin-V–FITC/PI. Living cells are marked in gray, early apoptotic cells in white (Annexin V
positive), late apoptotic cells in black (Annexin V and PI positive) and necrotic cells in spotted gray (PI positive). (b) Mitochondrial membrane potential (DCm) of cells was
determined by flow cytometry using JC-1 as mitochondrial selective dye. MCF7 and MDA-MB-231 cells were treated with 100 and 300 nM ChA for 24 h. (c) Mitochondrial
cytochrome C content in cells (MCF7, MDA-MB-231) treated for 24 h with ChA (100 nM, 300 nM) was measured via flow cytometry. (d) Western blot analysis of procaspase-9
and cleavage of PARP as parameters for activation of caspase-9 and effector caspases, respectively, was performed using cells exposed to ChA (100 and 300 nM, 24 h). The
graphs represent the quantitative analysis of the band intensities of Pro-caspase 9 and the PARP cleavage product. Blotting for GAPDH serves as loading control. A
representative blot out of three is shown. Bars represent the mean ±S.E.M. of three independent experiments performed in triplicates, ***Po0.001 (one-way ANOVA,
Bonferroni)
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abrogated, thus finally resulting in inhibition of cytochrome C
release.
ChA inhibits PKCe activation by trapping in actin
bundles. Ser112-phosphorylation of Bad as well as the
interaction of HkII with VDAC are known to be regulated by
PKCe.17 As PKCe contains an actin-binding site, our
working hypothesis focused on PKCe as a link between
the effect of ChA on actin CSK and the induction of
apoptosis via mitochondrial activation. As a first step to
verify this idea, the postulated interaction of actin CSK and
PKCe was confirmed (Figure 4). Immunostaining of mGFP-
b-actin-transfected MCF7 cells showed an enrichment of
PKCe in ChA-induced actin bundles at 6 and 24 h after
treatment (Figure 4a). To control that we are not observing
a compound-specific effect of ChA, two other actin-
polymerizing agents (jasplakinolide and doliculide) were
used in this colocalization assay, and also here it could be
shown that PKCe is trapped in actin bundles induced by
jasplakinolide and doliculide (Supplementary Figure 2).
Interestingly, PKCa, which does not contain an actin-
binding site, shows no colocalization in ChA-induced actin
lumps (Supplementary Figure 3). Analysis of cytosolic and
cytoskeletal fractions of MDA-MB-231 (Figure 4b) and
MCF7 cells (Supplementary Figure 4) showed increased
actin content in the CSK fraction after ChA treatment
compared with control cells that, importantly, is accom-
panied by enhanced PKCe protein levels, but not PKCa.
GAPDH in the cytoskeletal fraction serves as impurity
control for cytoplasmic contaminants. These data point to a
specific interaction between actin CSK and PKCe and its
modulation via ChA treatment. In fact, ChA affects
activation of PKCe, as shown in Figure 4c. As translocation
of PKCs to the cell membrane is a typical hallmark for their
activation, MDA-MB-321 cells were stained for PKCe after
exposure to phorbol-13-myristate-12-acetate (PMA), a
common inducer of PKCs (1 mM, 30 min). PMA-stimulated
cells clearly display PKCe protein localized on the cellular
membrane, whereas treatment with ChA results in a
significant decrease of PKCe at the plasma membrane
quantified by counting the respective cells (Figure 4c).
Taken together, Figure 4 displays a trapping of PKCe and
impaired PKCe activation as consequence of ChA-induced
polymerization of actin CSK.
ChA-induced cell death is dependent on PKCe expression.
In order to prove the link between PKCe and ChA-induced
apoptosis, cells overexpressing PKCe were analyzed for their
apoptotic response upon ChA treatment (Figure 5a). Over-
expression of PKCe was verified by western blot analysis
(insets; Figure 5a) and does not affect itself cell viability (data
not shown). PKCe-transfected MCF7 and MDA-MB-231 cells
show a significant decrease in sensitivity toward ChA
treatment compared with cells transfected with empty vector
plasmid, thus verifying the importance of PKCe in cell death
induction mediated by Chondramide. This was further
support by siRNA experiments in MDA-MB-231. Down-
regulation of PKCe resulted in an increased rate of Annexin
V-positive cells, indicating the induction of apoptosis by PKCe
silencing (Supplementary Figure 5).
ChA treatment displays tumor cell specificity. The
distinct role of PKCe in ChA-induced cancer cell apoptosis
and even more its selectivity toward tumor cells was
demonstrated by another set of experiments: the effect of
ChA on the two tumor cell lines (MCF-7, MDA-MB-231) was
compared with that on the nontumorigenic breast epithelial
cell line MCF10-A (Figure 5b). Treatment with 300 nM ChA
disrupts actin CSK in MCF10-A as well (Supplementary
Figure 6); however, MCF10-A cells show no increased cell
death rate in contrast to MCF7 and MDA-MB-231 cells
(Figure 5b). To link PKCe to induction of apoptosis, we
compared PKCe protein levels in all three cell lines. Of note,
MCF10-A nontumorigenic cells express much less PKCe
protein than MCF7 and MDA-MB-231 cancer cells
(Figure 5c). A similar picture was observed when analyzing
breast tissue from patients. Human breast cancer tissues
display a massive expression of PKCe, whereas healthy
breast tissues show only weak staining for PKCe besides in
the acini of breast glandular cells (Figure 5d). In sum, ChA-
induced apoptosis is mediated by actin CSK disruption and is
highly depending on the expression of PKCe in cells.
Chondramide reduces tumor growth and induces actin
polymerization, PKCe trapping and apoptosis in vivo. Using
a MDA-MB-231 xenograft mouse model administration of
0.75mg/kg, Chondramide was shown to significantly reduce
tumor growth as monitored by tumor volume (Figure 6a). Tumor
tissue was examined for apoptotic cells (TUNEL assay) and
showed a significant increase of apoptotic nuclei in the
Chondramide-treated group compared with control tissue
(Figure 6b). Furthermore, we analyzed actin CSK and PKCe in
cryosections of tumor tissue. Chondramide also leads in vivo to a
disruption of actin CSK (especially on the border of tumors) and,
moreover, PKCe is localized in actin bundles in Chondramide-
treated tumors (Figure 6c). In sum, this set of experiments
confirms Chondramides’ cell death-inducing mechanism in vivo.
The cartoon in Figure 6d summarizes the postulated molecular
mechanism of Chondramide’s mode of action.
Discussion
The actin and microtubule cytoskeletons play pivotal roles in
cancer biology as they regulate tumor relevant processes, for
example, cell cycle, morphogenesis or migration.30 Whereas
drugs such as vinca alkaloids or taxanes that target
microtubules are well established in the clinic,31 compounds
binding to the actin CSK are still far away from their
therapeutical application. One reason might be lack of
knowledge on their tumor-specific mechanism of action.
The data communicated here provide a conceptual frame-
work for actin-polymerizing agents such as Chondramide as
tumor cell-specific cytotoxic drugs. The major findings were as
follows. (1) The actin CSK is involved in specific apoptotic
signaling via PKCe and regulation of MPT. As PKCe is
overexpressed in tumor cells, a tumor cell-selective mode of
action is proposed. (2) Actin-targeting Chondramide masters
the challenge of isoform-specific inhibition of PKC, namely
protumorigenic PKCe. (3) Chondramide induces apoptosis and
displays in vivo efficacy via disruption of PKCe signaling.
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Pharmacological interruption of actin dynamics has been
reported before to lead to cell death, but the exact mechan-
isms remain unclear.1 Posey et al.32 hypothesized a role of
gelsolin, an actin-binding protein, for apoptosis induced by
another actin-polymerizing natural compound named jaspla-
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have no impact on apoptosis induction by jasplakinolide. We
used Chondramide as a chemical tool to learn more about
actin-specific apoptotic signaling. Chondramide, similar to
jasplakinolide,33 hyperpolymerizes the actin cytoskeleton,
induces agglomeration of actin that assembles over time
and forms massive amorphous actin bundles that contain
actin-binding proteins as reported previously.34 Our driving
strategy was to search for regulators of cell death containing
an actin-binding site and to examine whether they might be
trapped within these actin structures and thereby display
decreased functionality. We came up with PKCe, a member of
the PKC family, that, on one hand, possesses an actin-binding
motif3,5 and is, on the other hand, a crucial regulator of several
prosurvival pathways.6–11
The PKC family has been an exciting target for drug
discovery especially in cancer ever as they were identified as
intracellular receptors for the tumor-promoting agents phorbol
esters.35 However, major challenges such as dissecting the
contribution of PKC isozymes to cancer progression or
developing modulators specific for the PKC isozymes are still
to be met. PKCs are either pro-mitogenic or inhibit cell cycle
progression depending on isozyme and cell type. PKCa and
PKCD, for instance, promote anti-mitotic responses36 in tumor
cells, whereas PKCe is required for cancer cell survival.10,11
Furthermore, PKCe has been shown to be overexpressed in
various types of cancer including breast cancer,6,9 supported
by our own data. PKCe mediates oncogenic activities as it
affects the activity of transcription factors like ATF2, NF-kB
and Stat3,12,37,38 and also addresses distinct targets in the
apoptotic machinery of cells such as the BH3-only Bcl2-family
protein Bad. Bad exerts its pro-apoptotic functions in a
dephosphorylated form and PKCe is known to directly
phosphorylate Bad on serine 112, thus inhibiting the pro-
apoptotic activity of Bad17,39,40 by preventing MPT17 and
hence the onset of apoptosis. PKCe counteracts the MPT not
only via inactivation of Bad but also by maintaining the
complex of VDAC and HkII at the outer mitochondrial
membrane. Phosphorylation of VDAC4 as well as phospho-
rylation of the transcription factor ATF2, which then attenuates
apoptosis through saving the VDAC/Hk interaction,37 are
discussed as mechanisms for the prosurvival features of
PKCe. The association between the glycolytic enzyme HkII
and VDAC has been reported to be specific for cancer cell
mitochondria and thus its disruption promises tumor cell-
specific apoptosis.14 Inhibition of PKCe leads to MPT because
of loss of VDAC/Hk complex as well as loss of inactivated Bad,
both of which could be clearly demonstrated for Chondramide
treatment. Our work provides evidence for MPT as target in
apoptosis induction by PKCe inhibition in Chondramide-
treated cells. Supplementary Data show that cyclosporin A,
which normally blocks the Ca2þ -induced MPT, is not able to
prevent mitochondrial swelling (i.e., the MPT) in isolated
mitochondria from cells treated with Chondramide, thus
further supporting the involvement of MPT. Moreover, our
data offer an explanation of how changes in actin CSK
dynamics lead to cell death and proposes actin CSK as a
specific antitumor target.
As mentioned above, identification of isozyme-selective
modulators of PKCs has been a major challenge taken up by
various approaches such as the development of ATP-
competitive small-molecule inhibitors that bind to the catalytic
domain of the kinase, phorbol ester derivatives that mimic the
binding of diacylglycerol or peptides that prevent the anchor-
ing of the PKC to its RACK (receptor of activated C-kinase)
that brings the activated enzyme to its substrate.35 Our data
propose Chondramide as an indirect PKCe-specific inhibitor
based on the fact that particularly PKCe because of its actin-
binding site is trapped by Chondramide-induced actin poly-
merization. The role of PKCe as a promising tumor-specific
therapeutic target and as a major player in Chondramide-
induced tumor cell death is supported by two facts. First,
nontumor cells (MCF-10A breast epithelial cells) show low
level of PKCe and are not sensitive to Chondramide. Second,
PKCe overexpression, leading to free PKCe that is not trapped
in actin bundles, rescues Chondramide-induced apoptosis.
Importantly, Chondramide shows in vivo efficacy. Treat-
ment of mice bearing a xenograft breast tumor (MDA-MB-231
cells) with Chondramide leads to reduction of tumor growth by
inducing apoptosis through PKCe trapping in actin bundles.
Our data link actin, a target distributed in all eukaryotic cells,
to the cancer-specific protein PKCe and open new therapeu-
tical approaches by using actin-overpolymerizing com-
pounds. Thus, our work encourages comprehensive
pharmacological evaluation of this class of actin-targeting
agents in tumor therapy.
Materials and Methods
Reagents. Chondramide A (chemical structure Supplementary Figure 1) was
isolated as described previously29 and dissolved in dimethylsulfoxide (DMSO). The
PKC activator PMA was purchased from Merck Millipore (Darmstadt, Germany)
and dissolved in DMSO. Jasplakinolide was purchased from Sigma-Aldrich
(Taufkirchen, Germany) and Doliculide was a gift from Professor Karl-Heinz
Altmann (ETH Zurich, Zurich, Switzerland).
Cell culture. The human epithelial breast cancer cell line MCF7 was
purchased from the DSMZ (Braunschweig, Germany) and maintained in RPMI-
1640 medium supplemented with 10% heat-inactivated fetal calf serum (FCS,
Biochrom AG, Berlin, Germany), 1% pyruvate (Sigma-Aldrich), 125mg/l insulin
(Sigma-Aldrich), 1% nonessential amino acids (PAA, Pasching, Austria) and 1%
penicillin/streptomycin (Sigma-Aldrich) at 371C and 5% CO2. MCF10-A
nontumorigenic epithelial cells were from ATCC (Manassas, VA, USA) and
cultivated in RPMI-1640 medium supplemented with 5% horse serum (PAA),
Insulin 125mg/l (Sigma-Aldrich), EGF 100 ng/ml (PeproTech, Hamburg, Germany),
hydrocortisone 0.8mg/ml (Sigma-Aldrich), cholera toxin 0.16mg/ml (Sigma-Aldrich)
Figure 3 Treatment with Chondramide A (ChA) leads to the dislocation of Hexokinase II (HkII) from mitochondria and activation of pro-apoptotic Bad. (a) MCF-7 cells
transfected with mGFP-b-actin were treated with 300 nM ChA for 6 h, fixed and co-stained with Mitotracker red CMX-ROS and anti-Hexokinase II antibody followed by
confocal microscopic analysis. Scale bar indicates 10 mm. Representative images are shown. (b) Western blot of HkII in mitochondrial fraction of MDA-MB-231 cells treated
with 300 nM ChA for 6 and 24 h. Cytosolic and mitochondrial fractions were separated. Immunoblotting for b-tubulin and COX IV were used for controlling purity of
mitochondrial fraction and loading control, respectively. Representative blot of the mitochondrial fraction and the respective quantification is shown. (c) Western blot analysis
for Bad and phospho-(Ser112)-Bad in MCF7 and MDA-MB-231 cells treated with 100 and 300 nM ChA for 6 h and quantitative analysis of band intensities. (d) MCF7 cells
transfected with mGFP-b-actin were treated with 300 nM ChA for 6 h, fixed and co-stained with Mitotracker red CMX-ROS and anti-Bad-antibody followed by confocal
microscopic analysis. Scale bar indicates 10 mm. Representative images are shown. Each experiment was performed independently three times
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and 1% penicillin/streptomycin. MDA-MB-231 was purchased from cell lines
service (Eppelheim, Germany) and maintained in DMEM high glucose (PAA)
supplemented with 10% FCS and 1% penicillin/streptomycin.
Transfection of mGFP-b-actin in MCF7. MCF7 cells were
transfected with pCAG-mGFP-b-actin using the FuGene transfection
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Figure 5 PKCe overexpression rescues cells from Chondramide A (ChA)-induced apoptosis and noncancerous cells are less susceptible to ChA. (a) MCF7 and MDA-MB-
231 cells were transfected with FLAG.PKCe or an empty vector and treated with 300 nM ChA for 24 h. The number of dead cells was analyzed using the propidium iodide (PI)
exclusion assay for MCF7 cells and Annexin V staining for MDA-MB-231 cells. Overexpression of PKCe was confirmed by western blot (insets). The graphs show the results
normalized to the according control. Each experiment was independently performed three times. (b) The adenocarcinoma cell lines MCF7, MDA-MB-231 and the
nontumorigenic epithelial breast cell line MCF10-A were evaluated for their responsiveness to ChA by monitoring PI-positive cells after 24 h. (c) Comparison of PKCe levels is
shown in MCF7, MDA-MB-231 and MCF10-A via western blot (graph shows quantification) as well as via immunohistochemistry. GADPH and actin serve as loading control.
Each experiment was independently performed three times. (d) Representative PKCe tissue stainings of healthy breast tissue and mammary tumor tissue. Nuclei are
counterstained with hematoxylin. Bars represent the mean±S.E.M. of three independent experiments performed in triplicates, *Po0.05, **Po0.01, ***Po0.001 (one-way
ANOVA, Bonferroni)
Figure 4 PKCe colocalizes with Chondramide A (ChA)-induced actin bundles, accumulates in the cytoskeletal fraction (CSK) and shows decreased activity upon ChA
treatment. (a) MCF7 cells were transfected with mGFP-b-actin and incubated with 300 nM ChA for 6 and 24 h. Cells were fixed and stained for PKCe. Yellow color in merged
images indicates colocalization of PKCe with actin bundles. Nuclei were stained by Hoechst 33342. Scale bar indicates 10 mm. (b) Cytosolic and cytoskeletal fractions of MDA-
MB-231 cells were isolated, resolved by SDS-PAGE and immunoblotted using antibodies against PKCa, PKCe, actin and GAPDH. (c) PKCe activation was determined via
monitoring the translocation to the plasma membrane. MDA-MB-231 cells treated with 100 and 300 nM ChA for 6 h were costimulated with PMA (1 mM, 30 min), fixed and
stained for PKCe. Quantification of cells with activated PKCe was done by analyzing at least 80 cells per group for their PKCe membrane localization (confocal microscopy).
Shown are representative images, and white arrows indicate cells with active PKCe. Scale bar indicates 10mm. The graph shows a normalized statistical analysis. All
experiments were performed independently three times. Bars represent the mean ±S.E.M. of three independent experiments performed in triplicates, *Po0.05, **Po0.01
(one-way ANOVA, Bonferroni)
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instructions. pCAG-mGFP-actin was a gift of Ryohei Yasuda41 (Addgene plasmid
21949, Cambridge, MA, USA).
Fluorescence recovery after photobleaching. MCF7 cells transfected
with mGFP-b-actin were seeded in ibidi-m-slides (ibidi, Martinsried, Germany) and
incubated in the climate chamber of a Zeiss LSM 510 (Zeiss, Jena, Germany)
confocal microscope at 5% CO2, 371C. Regions of interest (ROIs) of equal size
were chosen in untreated and ChA (300 nM, 0.5 h)-treated cells and were
bleached by high laser energy (488 nm). Images were taken every 5 s, lasting for
B2.5 min and the fluorescence intensity within the ROI was measured. Cells were
randomly chosen for bleaching and quantification of fluorescence recovery was
done using the LSM image browser software (Zeiss).
Quantification of cell death. For analysis of membrane phosphatidylserine
exposure, phosphatidylserine switch to the outer leaflet of the plasma membrane
was analyzed by Annexin-V staining using the respective apoptosis detection kit
(ebioscience, San Diego, CA, USA) according to the manufacturer’s instructions.
Cells were analyzed by a FACSCalibur cytometer (Becton Dickinson, Heidelberg,
Germany).
For propidium iodide exclusion assay, cells were harvested, washed, exposed to
a solution of propidium iodide (50mg/ml) (Sigma-Aldrich) in PBS and immediately
analyzed by flow cytometry using a Becton Dickinson FACSCalibur.
Mitochondrial potential (DWm). Cells were harvested and incubated
with JC-1 (Alexis Biochemicals, Loerrach, Germany; 1.25 mM, 371C, 30 min).
Mitochondria with an intact potential display JC-1 red fluorescing aggregates,
whereas in mitochondria with disrupted potential JC-1 is monomeric and green
fluorescent. The shift in fluorescence was monitored by a FACSCalibur cytometer
(Becton Dickinson) using channel FL1-H for green fluorescence. Membrane
potential and swelling of isolated mitochondria was assessed by Rh123
fluorescence quenching as described in literature.42
Cytochrome C release. Analysis of cytochrome C release was performed
as previously described.43 Briefly, cells were incubated in a digitonin-containing
buffer for 30 min on ice (0.2 mM Na-EGTA, 100 mM KCl, 50 mg/ml digitonin, PBS),
fixed with 4% PFA for 20 min and unspecific binding was blocked (3% BSA, 0.05%
Saponine (Sigma-Aldrich), 1 h, RT) before incubation with cytochrome C antibody
overnight at 41C and staining with the secondary antibody for 1 h. Cytochrome C
antibody was purchased from Cell Signaling Technology (Danvers, MA, USA) and
secondary goat-anti-rabbit-Alexa-488 antibody was obtained from Invitrogen
(Darmstadt, Germany). Fluorescence was detected using a FACSCalibur
cytometer (Becton Dickinson). A decrease in fluorescence intensity indicates a
loss of mitochondrial cytochrome C that is washed out after cell membrane
permeabilization.
Western blot analysis. Cells were harvested, washed and lysed on ice with
a buffer containing 2 mM EDTA, 137 mM NaCl, 10% glycerol, 2 mM Na4P2O7,
20mM Tris-base, 1% Triton-X 100, 20 mM sodiumglycerolphosphate, 10 mM NaF,
2 mM Na3VO4, 1 mM phenylmethylsulfonylfluoride and Complete protease inhibitor
(Roche, Mannheim, Germany). Equal amounts of protein were separated using
SDS-PAGE and blotted on nitrocellulose membranes (GE Healthcare, Munich,
Germany). Membranes were probed with antibodies as indicated. Following
antibodies were used: actin (Merck Millipore), Bad/phospho-Ser112-Bad,
b-Tubulin, Caspase 9, COX IV, Hexokinase II, PARP (Cell Signaling Technology),
GAPDH, PKCa, PKCe (Santa Cruz Biotechnology, Dallas, TX, USA), goat-anti-
mouse IRDye 800 cw (LI-COR Biosciences, Lincoln, NE, USA), goat-anti-rabbit-
800 (Invitrogen), HRP goat-anti-mouse (Santa Cruz Biotechnology) and
HRP-goat-anti-rabbit (Bio-Rad, Hamburg, Germany). For detection the enhanced
chemiluminescence system (GE Healthcare) or the Odyssey infrared imaging
system (LI-COR biosciences) was used.
Immunostaining and confocal microscopy. Cells were seeded in
ibidi-m-slides (ibidi), treated as indicated, washed, fixed with 4% paraformalde-
hyde, permeabilized with 1% Triton-X 100 and incubated with 1% bovine serum
albumin solution to block unspecific binding of antibodies. The following primary
antibodies were incubated overnight at 41C: PKCa, PKCe (Santa Cruz
Biotechnology) and Hexokinase II (Cell Signaling Technology). Goat-anti-rabbit-
Alexa647 antibody (Invitrogen) was used as secondary antibody and incubated
with 0.5mg/ml Hoechst 33342 (Sigma-Aldrich) for 2 h. Mitochondrial staining was
achieved by using MitoTracker Red CMXROS (Invitrogen) according to the
manufacturer’s instructions. Stainings were visualized using the confocal
microscope LSM 510 Meta (Zeiss).
Cell fractionations. For cytosolic–mitochondrial fractionation, mitochon-
drial fractions were prepared as previously described.44 In brief, cells were
harvested and lysed with a buffer containing digitonin (80 mg/ml) and
centrifuged at 500 g to remove cell debris. Supernatants were collected
and centrifuged at 12 000 g to separate the mitochondrial fraction from the
cytosolic one. The pellet containing the mitochondrial fraction was washed with
ice-cold PBS and permeabilized using 0.1% Triton-X 100. For functional
analysis, mitochondria were isolated as described previously.45 Protein content
was determined via Bradford and equal amounts of protein were separated
using SDS-PAGE.
For cytosolic–cytoskeletal fractionation, cytoskeletal preparation was modified
from Zeidman et al.5 Briefly, cells were lysed for 20 min on ice with the lysis buffer
mentioned in the western blot section. Lysates were centrifuged at 500 g for
10 min to remove nuclei and cell debris. Supernatants containing cytosolic and
cytoskeletal proteins were centrifuged at 12 000 g for 15 min to separate CSK.
Proteins of supernatant and CSK pellet were separated using SDS-PAGE and
blotted on nitrocellulose membrane (GE Healthcare).
Overexpression of PKCe. FLAG.PKCepsilon plasmid was a gift of Alex
Toker46 (Addgene plasmid 10795). MCF7 cells were transfected using the Amaxa
Nucleofector kit V (Lonza) according to the manufacturer’s instructions. MDA-MB-
231 cells were transfected using FuGene HD transfection kit (Promega).
pcDNA3.1 (Invitrogen) was used as empty vector control. Upregulation of PKCe
was confirmed on protein level via western blot. At 24 h after transfection, cells
were treated with ChA at indicated concentrations.
Downregulation of PKCe. MDA-MB-231 cells were transfected for 72 h
using Dharmafect transfection reagent (GE Heatlthcare, Buckinghamshire, UK)
according to the manufacturer’s instructions. The siRNA used for the experiments
was ON-TARGETplus PRKCE siRNA from Dharmacon (GE Healthcare).
Staining of mammary tissue sections. Tumor and healthy breast
tissues were fixed in formalin and embedded in paraffin blocks. Sections were
stained with anti-PKCe antibody (Abcam, San Francisco, CA, USA) and visualized
with the Vectastain ABC Kit (Vector Laboratories, Burlingame, CA, USA)
according to the manufacturer’s instructions. Four control tissues and six tumor
tissues were analyzed and images were taken on an Olympus BX41 microscope
(Olympus, Center Valley, PA, USA) with a 20-fold magnification.
In vivo mouse xenograft model. For the subcutaneous xenograft model,
5 106 MDA-MB-231 cells in Matrigel/PBS (1:1) were injected subcutaneously in
Figure 6 Chondramide affects tumor growth in vivo via actin polymerization-induced abrogation of PKCe signaling. (a) Tumor volume of female SCID mice harboring a
MDA-MB-231 tumor in their flank that were either treated with solvent control (DMSO) or 0.75 mg/kg/day Chondramide. Significance analysis was performed using Student’s
t-test with *Po0.05, **Po0.01. (b) Statistical analysis of TUNEL-stained paraffin sections. Six fields per tumor were visualized and counted. (c) Cryosections of tumors were
stained for actin (red), PKCe (green) and nuclei (blue). Scale bar indicates 50 mm. Representative images of a control and Chondramide-treated tumor borders are shown.
Inserts in the merged images show a magnification of a few single cells. Bars represent the mean ±S.E.M. of three independent experiments performed in triplicates,
*Po0.05 (one-way ANOVA, Bonferroni). (d) Cartoon illustrating the mode of action of ChA. Physiological state: PKCe activity leads to stabilization of the Hexokinase II/VDAC
interaction and phosphorylation of Bad, both of which prevent efflux of cytochrome C and support survival of cancer cells. Chondramide A treatment: ChA leads to actin
hyperpolymerization and impairment of PKCe signaling, thereby to destabilization of the Hexokinase II/VDAC complex and dephosphorylation of Bad, resulting in cytochrome
C release and induction of apoptosis
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the flank of female SCID (C.B-17/IcrHanHsd-Prkdcscid, Harlan, Tampa, FL, USA)
mice. At 9 days after tumor cell injection, 0.75 mg chondramide/kg in PBS/5%
Solutol (BASF, Ludwigshafen, Germany) was injected intraperitoneally three times
a week. After 34 days, mice were killed and tumor growth and tumor weight of
control (n¼ 10) and Chondramide-treated mice (n¼ 10) was determined. Tumor
volume was calculated every second day according to the formula V¼ a b2/2
(a¼ largest side of the tumor and b¼ the largest side vertical to a). Average
tumor volumes of the two groups were compared over time. Tumor tissues were
either frozen in liquid nitrogen or fixed in formalin. Cryosections were stained for
actin with rhodamine phalloidin (Invitrogen) and anti-PKCe-antibody (Abcam)
followed by incubation with anti-rabbit secondary antibody conjugated with Alexa
488 (Invitrogen). Formalin preserved sections were embedded in paraffin and
stained for apoptotic cells by ApopTag Fluorescein In Situ Apoptosis Detection Kit
(Merck Millipore) according to the manufacturer’s instructions. TUNEL-positive
cells were visualized with a Zeiss confocal microscope. Six randomly
chosen images of each tumor were counted for TUNEL-positive nuclei. All animal
procedures were approved and controlled by the local ethics committee
and carried out according to the guidelines of the German law of protection
of animal life.
Statistics. Statistical analysis was performed using the GraphPad Prism 5.0
software (La Jolla, CA, USA). Error bars indicate ±S.E.M. One-way ANOVA with
Bonferroni post-test or Student’s t-test was used as significance analysis.
A P-value of o0.05 was considered statistically significant.
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